Latest Transplant rejection Stories
Findings could help provide better donor-recipient matches and tailor recipients' treatments after kidney transplantation Highlights: -The detection of preformed donor-specific antibodies by newer tests, despite negative results from traditional tests, nearly doubles a kidney transplant recipient's risk for rejection. -It also increases the risk of kidney failure by 76%. Nearly 17,000 kidney transplants take place each year in the United States. Kidney transplant recipients who...
HORSHOLM, Denmark, Oct. 10, 2012 /PRNewswire/ -- Veloxis will give two upcoming data presentations that further define the profile of LCP-Tacro compared to other tacrolimus formulations. The first study demonstrates the potentially flexible dosing that may improve dosing convenience for transplant patients. A second study demonstrates the enhanced bioavailability of tacrolimus driven by LCP-Tacro's proprietary formulation, compared to another once-daily tacrolimus formulation, which...
NORTHBROOK, Ill., Sept. 24, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Developed by Astellas,...
ALEXANDRIA, Va., Sept. 12, 2012 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced a $15 million round of debt financing for XDx, Inc. Silicon Valley Bank acted as co-lender in this transaction. Proceeds of the loan will be used for working capital and to fund the development of new diagnostic applications using XDx's molecular expression technology. "XDx is a pioneer...
SAN ANTONIO, Aug. 7, 2012 /PRNewswire-USNewswire/ -- For kidney failure patients with living donors who are not a match, kidney paired donation offers an alternative with outstanding results, concludes a study published in this month's edition of the American Journal of Transplantation. Doctors at Methodist Specialty and Transplant Hospital published the article, "Single-Center Kidney Paired Donation: The Methodist San Antonio Experience," based on the results of a three-year study on...
Findings may affect how doctors treat allergic inflammation and organ transplant rejection A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells. In particular, the team uncovered that a particular cell surface molecule, known as OX40, is a powerful inducer of new T helper cells that make copious amounts of...
ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive...
CHILLY-MAZARIN, France, June 14, 2012 /PRNewswire/ -- InGen BioSciences, specialised in the development and commercialisation of mono and multiparametric in vitro diagnostic tests announced a new exclusive partnership with Cylex Incorporated (Columbia, Maryland,...
In the news release, Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro(TM) in Stable African-American Kidney Transplant Patients at American Transplant Congress (ATC), issued 31-May-2012 by Veloxis Pharmaceuticals A/S over PR Newswire, we are advised by the company that the end of the second paragraph should read "second quarter of 2013" rather than "second quarter of 2012" as originally issued inadvertently. The complete, corrected release...
HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely converted from twice-daily Prograf(®) to once-daily LCP-Tacro. In addition, there was a trend toward fewer biopsy-proven acute rejections (BPARs) with LCP-Tacro compared to Prograf. The analysis will...
